Body growth assessment in children with IgE-mediated cow's milk protein allergy fed with a new amino acid-based formula

Rita Nocerino; Serena Coppola; Laura Carucci; Lorella Paparo; Anna Fiorenza De Giovanni Di Santa Severina; Roberto Berni Canani

doi:10.3389/falgy.2022.977589

Body growth assessment in children with IgE-mediated cow's milk protein allergy fed with a new amino acid-based formula

Front Allergy. 2022 Sep 5:3:977589. doi: 10.3389/falgy.2022.977589. eCollection 2022.

Authors

Rita Nocerino^{1

2}, Serena Coppola^{1

2}, Laura Carucci^{1

2}, Lorella Paparo^{1

2}, Anna Fiorenza De Giovanni Di Santa Severina^{1

2}, Roberto Berni Canani^{1

2

3

4}

Affiliations

¹ Department of Translational Medical Science, University of Naples Federico II, Naples, Italy.
² ImmunoNutritionLab at CEINGE Advanced Biotechnologies, University of Naples Federico II, Naples, Italy.
³ European Laboratory for the Investigation of Food-Induced Diseases, University of Naples Federico II, Naples, Italy.
⁴ Task Force on Microbiome Studies, University of Naples Federico II, Naples, Italy.

Abstract

Background: Amino acid-based formula (AAF) is a relevant dietary option for non-breastfed children. The present study was designed to evaluate the body growth pattern in cow's milk protein allergy (CMPA) children treated for 6 months with a new AAF.

Methods: This was an open-label, single arm study evaluating body growth pattern in immunoglobulin E (IgE)-mediated CMPA infants receiving a new AAF for 6 months. The outcomes were anthropometry (weight, length, head circumference), adherence to the study formula and occurrence of adverse events (AEs).

Results: Fifteen children [all Caucasian and born at term; 53.3% born with spontaneous delivery; 80% male; 80% with familial allergy risk; mean age (±SD) 3 ± 2.5 months at IgE-mediated CMPA diagnosis; mean age (±SD) 16.7 ± 5.9 months at enrolment, mean total serum IgE (±SD) 298.2 ± 200.4 kU/L] were included and completed the 6-month study. Data from fifteen age- and sex-matched healthy controls were also adopted as comparison. At baseline, all CMPA patients were weaned and were receiving the new AAF. All 15 patients completed the 6-month study period. For the entire CMPA pediatric patients' cohort, from baseline to the end of the study period, the body growth pattern resulted within the normal range of World Health Organization (WHO) growth references and resulted similar to healthy controls anthropometric values. The formula was well tolerated. The adherence was optimal and no AEs related to AAF use were reported.

Conclusions: The new AAF ensured normal growth in subjects affected by IgE-mediated CMPA. This formula constitutes another suitable safe option for the management of pediatric patients affected by CMPA.

Keywords: anthropometric measurements; diet therapy; food allergy; hypoallergenic formula.